FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+37.43%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$1.3B
AUM Growth
+$1.3B
(+23%)
Cap. Flow
+$129M
Cap. Flow
% of AUM
9.97%
Top 10 Holdings %
Top 10 Hldgs %
67.1%
Holding
47
New
6
Increased
10
Reduced
7
Closed
4
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$46.4M |
| 2 |
ALLK
Allakos
ALLK
|
$29.3M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
$28.6M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$21.5M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$14M |
Top Sells
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$47.9M |
| 2 |
Viridian Therapeutics
VRDN
|
$11.3M |
| 3 |
Vaxcyte
PCVX
|
$5.76M |
| 4 |
Krystal Biotech
KRYS
|
$5.37M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$1.64M |
Sector Composition
| 1 | Healthcare | 98.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
HilleVax
HLVX
$105M
| $167M | 12.84% | 9,758,359 +472,677 | +5% | +$8.08M |
|
2
Arcutis Biotherapeutics
ARQT
$1.86B
| $166M | 12.78% | 8,684,232 +250,000 | +3% | +$4.78M |
|
|
3
Phathom Pharmaceuticals
PHAT
$864M
| $93.2M | 7.17% | 8,407,152 +2,579,737 | +44% | +$28.6M |
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $83.9M | 6.46% | 4,265,559 +670,533 | +19% | +$13.2M |
|
5
Syndax Pharmaceuticals
SNDX
$1.41B
| $82M | 6.31% | 3,412,838 +217,435 | +7% | +$5.22M |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $80.4M | 6.19% | 3,827,781 +260,869 | +7% | +$5.48M |
|
|
7
Krystal Biotech
KRYS
$4.27B
| $71M | 5.47% | 1,018,388 -77,019 | -7% | -$5.37M |
|
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $46.4M | 3.57% | +1,894,000 | New | +$46.4M |
|
|
IMGO
9
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $44.7M | 3.44% | 2,971,274 | – | – |
|
|
10
Vaxcyte
PCVX
$4B
| $37.1M | 2.86% | 1,547,405 -240,000 | -13% | -$5.76M |
|
11
Cogent Biosciences
COGT
$1.69B
| $30.9M | 2.38% | 2,074,154 -20,000 | -1% | -$298K |
|
12
Tarsus Pharmaceuticals
TARS
$2.47B
| $30.6M | 2.36% | 1,787,527 | – | – |
|
|
ALLK
13
DELISTED
Allakos
ALLK
| $29.3M | 2.26% | +4,792,000 | New | +$29.3M |
|
14
Crinetics Pharmaceuticals
CRNX
$2.92B
| $27.8M | 2.14% | 1,414,823 | – | – |
|
|
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
| $26.7M | 2.06% | 2,549,671 +467,578 | +22% | +$4.9M |
|
16
AnaptysBio
ANAB
$569M
| $23M | 1.77% | 899,700 | – | – |
|
17
KalVista Pharmaceuticals
KALV
$678M
| $22.8M | 1.76% | 1,572,192 | – | – |
|
|
ALPN
18
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $21.5M | 1.66% | 2,985,757 | – | – |
|
|
VRNA
19
Verona Pharma
VRNA
$9.16B
| $21.5M | 1.65% | +2,099,541 | New | +$21.5M |
|
|
FLACU
20
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| $15.2M | 1.17% | 1,501,000 | – | – |
|
21
Merus
MRUS
$4.98B
| $15M | 1.15% | 746,479 +72,500 | +11% | +$1.45M |
|
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $14M | 1.08% | +857,338 | New | +$14M |
|
23
Replimune Group
REPL
$422M
| $13.9M | 1.07% | 806,267 | – | – |
|
|
GRTS
24
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $13.5M | 1.04% | 5,237,348 | – | – |
|
25
Arvinas
ARVN
$568M
| $12.7M | 0.98% | 285,331 | – | – |
|